论文部分内容阅读
将 62例Ⅳ期恶性肿瘤患者随机分为治疗组 3 2例化疗合用艾迪注射液 ,对照组 3 0例单纯化疗 ,观察两组患者生活质量、肿瘤疗效、骨髓功能的变化及艾迪注射液的不良反应。治疗组在改善患者生活质量、保护化疗后骨髓功能方面明显优于对照组 ,差异有统计学意义 ,P <0 0 5 ,且无明显不良反应 ,对肿瘤疗效两组差异无统计学意义。初步研究结果提示 ,艾迪注射液是一个提高晚期恶性肿瘤患者生活质量的理想药物。
Sixty-two patients with stage IV malignant tumor were randomly divided into treatment group (n = 32), chemotherapy combined with Aidi injection and control group (n = 30). The quality of life, tumor efficacy and bone marrow function were observed in two groups. Adverse reactions. Treatment group in improving the quality of life of patients, protection of bone marrow function after chemotherapy was significantly better than the control group, the difference was statistically significant, P <0 05, and no significant adverse reactions, the efficacy of the two groups showed no significant difference. Preliminary findings suggest that Aidi Injection is an ideal drug for improving the quality of life in patients with advanced malignancies.